Health
Pfizer’s First Gene Therapy Gets US Nod for Clotting Ailment
- Beqvez will cost $3.5 million, mirroring CSL Behring’s product
- Therapy reduced bleeding 71% compared with standard treatment
This article is for subscribers only.
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
The treatment, called Beqvez, gained clearance for patients with hemophilia B, a rare bleeding disorder, Pfizer said Friday in a statement. Pfizer’s medicine is a one-time therapy designed to insert a correct copy of the mutated gene that causes hemophilia B, preventing the dangerous bleeding episodes that mark the disease.